The patent entitles the University of Rochester to royalties on the sale of all COX-2 inhibitors. Shortly after the patent was awarded, attorneys representing the University of Rochester filed an infringement suit in federal court against Searle, Chicago, and Pfizer Inc., New York, which jointly market Celebrex.
The patent entitles the University of Rochester to royalties on the sale of all COX-2 inhibitors. Shortly after the patent was awarded, attorneys representing the University of Rochester filed an infringement suit in federal court against Searle, Chicago, and Pfizer Inc., New York, which jointly market Celebrex.
"We've filed a lawsuit against Searle and Pfizer to ensure that our legal rights are preserved, though we intend to begin discussions with both companies in an effort to negotiate licensing agreements," said Terrance O'Grady, an attorney for the University.
Searle disputes the validity of the University of Rochester claim and said that it lacks novelty and enablement â two requirements of U.S. patent law.
The University's patent lacks novelty because COX-2 inhibitors are not a new invention, according to Searle patent lawyers, who added that a significant body of literature existed before the patent was filed in 1992 that described the potential benefits of treating people with COX-2 drugs. In lacking enablement, Searle maintains the patent fails to describe or teach, with any particularity, how to put the invention into practice and claims that the sweeping nature of the University's patent is flawed. According to Searle, the University patent is a method-of-treatment patent covering how to apply the concept in patients, in contrast to Searle's compound patent that specifically describes a molecule.
Searle also expressed disappointment about the way the suit was handled by the University. "We are disappointed to hear of this development from the media, rather than being contacted directly by the University of Rochester. Uncertainty in the market about such an important and beneficial pharmaceutical agent is not in anyone's best interest â particularly arthritis patients," said Richard U. De Schutter, senior executive vice president and chief administrative officer of Pharmacia Corp. "We have complete confidence in our COX-2 patent estate and will vigorously defend against this challenge." PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.